U.S. License Holder:
AstraZeneca AB
Date of License:
November-14-2017
Last Update:
Dec-15-2024
FDA-Approved Indications
FASENRA (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for:
Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype;
Treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).